Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...
TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with ...
Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...
Ten years of substantial work by Université de Montréal immunologist Nathalie Labrecque's team at the Montreal Clinical ...
Mouse cells tweaked to produce the tardigrade protein incurred less DNA damage than unaltered cells — hinting at a new tool for cancer patient care.
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...
A text message scam claiming that consumers owe money for fake, unpaid road tolls is continuing to proliferate across the U.S., and experts are warning recipients to exercise caution. The scam ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback